You are here: Industry Insights > Vibegron

News List

Altasciences Contributes to Vibegron Approval contractpharma
February 25, 2021
Altasciences has contributed to the recent FDA approval of Vibegron, a beta-3 adrenergic receptor (β3) agonist for the treatment of overactive bladder, conducting multiple early phase clinical trialsfor Urovant Sciences.
Urovant Collaboration, Sunovion Pharmaceuticals Sumitovant Biopharma Announces americanpharmaceuticalreview
July 01, 2020
Sumitovant Biopharma announced Urovant Sciences has entered into an exclusive three-year distribution agreement with Sunovion to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.
Vibegron Effective and Safe for Treating Overactive Bladder in Adults, Elderly Population: Presented at AUA firstwordpharma
May 09, 2019
A once-daily regimen of the oral beta3-adrenoceptor (AR) agonist vibegron is effective in the treatment of overactive bladder, including elderly populations, according to results of the phase 3 EMPOWUR trial ...